News of Note—Themis’ Chikungunya vaccine, Gardasil protests and more


Here is some other vaccine news of note for the week.

> The European Medicines Agency has granted Themis’ phase 2 chikungunya vaccine candidate Priority Medicines (PRIME) designation, which is designed to provide enhanced regulatory support. Release

> A group of women protested at Merck’s office in Hong Kong to express their unhappiness over a shortage of Gardasil 9 in the area and to urge the firm to increase the supply. South China Morning Post article

> Healthcare mogul Patrick Soon-Shiong plans to take public a cancer vaccine biotech later this year to finance the development of six candidates currently in clinical trials against nine tumor types. FierceBiotech article

> The FDA granted a priority review for Merck's Gardasil 9 in women and men ages 27 to 45 with a PDUFA date of Oct. 6, 2018. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.